ClinicalTrials.gg
Not yet recruitingNCT07404293Updated Feb 11, 2026

Zero CDE Technique for Lens Removal During FLACS

An interventional study of Femtosecond laser-assisted cataract surgery using Zero CDE in Cataract With a Nuclear Sclerosis Grade Between 1 to 3, sponsored by Bochner Eye Institute. Not yet recruiting at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Bochner Eye Institute · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Cataract with a site in Canada — 3 open to participants now, 3 under way, none of them phase 3. Cataract · Canada.

Planned enrollment
9th of 23
90 · median 68
Started
2026
with 1 other
No phase
18 of 33
1 open now
Registered
32nd of 33
by date
Lead sponsor
1 of 33
Bochner Eye Institute

Among the 33 studies in Cataract with a site in Canada, this one is the 9th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 18 with no phase, and was the 32nd registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

3 of the 33 studies in Cataract with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Cataract with a site in Canada, or all of them as a file.
02

Study summary

The Zero CDE (cumulative dissipated energy) technique facilitates cataract removal with no or minimal phaco energy. This is facilitated by a femtosecond laser, which pre-divides the cataractous lens nucleus into multiple small segments that can be aspirated without phaco energy being delivered to the eye. In the investigator's experience, this technique consistently shows a stable anterior chamber, a low complication rate, and a rapid return of vision following cataract surgery. This prospective study aims to document the outcomes with the zero CDE technique during femtosecond laser-assisted cataract surgery (FLACS).

03

Conditions studied

  • Cataract With a Nuclear Sclerosis Grade Between 1 to 3

Keywords

  • Zero CDE technique
  • FLACS
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over the age of 50 years with operable cataract of nuclear sclerosis grade 1 to 3 as measured by LOCS III grading system (patients with cortical or posterior subcapsular cataract of any grade will be eligible).
  • Patients must be able to provide written for participating in the study.
  • Preoperative best corrected visual acuity of 20/25 or worse.

Exclusion criteria

Exclusion Criteria:

  • Patients with corneal edema, corneal guttata, pseudoexfoliation, zonular dialysis, or other ocular anomalies (e.g., inflammation, uveitis, previous trauma, suspected microbial infection, glaucoma, and macular disease).
  • Patients wearing soft contact lenses will need to discontinue lens wear for 2 weeks, and hard contact lens wearers for one month prior to intraocular lens measurements.
  • Women patients of .
  • Patients undergoing arcuate keratotomy or other combined surgery with cataract.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Cataract removal with Zero CDE technique

    This is a single-arm, non-comparative, prospective study including cataract patients with a nuclear sclerosis grade between 1 to 3 who desire to undergo cataract surgery and IOL implantation at Bochner Eye Institute, Canada.

    Procedure: Femtosecond laser-assisted cataract surgery using Zero CDE

Interventions

  • ProcedureFemtosecond laser-assisted cataract surgery using Zero CDE

    In this single-arm, non-comparative study, patients with cataract grade 1-3 (LOCS III nuclear sclerosis) will undergo cataract removal with the Zero CDE technique that involves no or minimal phaco energy. This is facilitated by a femtosecond laser, which pre-divides the cataractous lens nucleus into multiple small segments that can be aspirated without phaco energy being delivered to the eye.

06

What researchers measure

Primary outcomes

  1. % of cataract cases completed with Zero CDE

    Time frame: Intraoperative

Secondary outcomes

  1. Among the cataract cases with zero CDE, o the average amount of balanced salt solution (BSS) (ml) used per case.

    Time frame: Intraoperative

  2. Among the cataract cases with zero CDE o % of cataract cases with corneal edema at one-day postop.

    Time frame: Postoperative Day 1

  3. Among the cataract cases with zero CDE o % of cataract cases with CME at any time up to 3 months postop.

    Time frame: Postoperative 2 weeks, 1 month and 3 months

  4. Among the cases requiring CDE, the amount of phaco energy used

    Time frame: Intraoperative

  5. Incidence of adverse events

    Time frame: Intraoperative, and postoperative Day 1, 2 weeks, 1 month, and 3 months

07

Study locations

1 site
  • Bochner Eye Institute
    Toronto, Ontario M5R1A9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 11 months later.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 11 months is below that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 11, 2026
StartEst.
Mar 15, 2026
Primary completionEst.
Mar 14, 2027
CompletionEst.
Jul 14, 2027
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404293
Lead sponsor
Bochner Eye Institute
Responsible party
Raymond Stein (Medical Director, Bochner Eye Institute) — Principal investigator
First posted
Feb 11, 2026
Start date
Mar 15, 2026 (estimated)
Primary completion
Mar 14, 2027 (estimated)
Completion
Jul 14, 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Raymond Stein, MD, FRCSC
Contact
raymondmstein@gmail.com
416-569-3806

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion